Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01614197 · ClinicalTrials.gov registry record · Phase 1
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase 1 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01614197 is a Phase 1 study that has completed, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 16 participants.
The verdict
NCT01614197, a Phase 1 study, has completed, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Methotrexate
- DRUG Hydrocortisone
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-07-03 |
| Est. Completion | 2020-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01614197
The ClinicalTrials.gov registry entry for NCT01614197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01614197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01614197 about?
NCT01614197 is a clinical study titled "A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma". This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).
What is the current status of trial NCT01614197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-07-03. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT01614197?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Methotrexate (DRUG), Hydrocortisone (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01614197?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.